Development of NT3 Genetically Engineered cells using human Lymphocytes.  by Xiao–feng, Ma et al.
Journal of Otology 2010 Vol. 5 No. 1
Correspondence to: GAO Xia, M.D., Associate Professor
Email: Xiagao213@yahoo.com.cn
Original Article
Development of NT3 Genetically Engineered cells using
human Lymphocytes.
MA Xiao-feng1, XU Lin1, CHEN Jie1, LU Ling1, GAO Xia1
1 Department of Otolaryngology & Head and Neck Surgery, the affiliated Drum Tower
Hospital of Nanjing University Medical College, Jiangsu 210008, China
Abstract Objective To establish a lymphocyte line capable of long survival and expressing human NT-3 to lay a
foundation for future animal and human cochlear gene transfection research. Methods We collected lymphocytes
from normal human blood via Ficoll fluid and added IL-2 into the serum culture medium to promote lymphocyte
growth. The NT3 cDNA was obtained by RT-PCR and ligated with the eukaryon vector which is pIRES-DsRed2 us⁃
ing T4DNA enzyme. The NT3 cDNA gene was transfected into the lymphocyte line using cationic liposome
（LP2000）. The lymphocytes transfected with NT3-cDNA were examined by RT-PCR and Western-blot methods.
Results We established a new method to extend in vitro lymphocytes survival time and to transfect NT3 into lympho⁃
cytes. The genetically engineered lymphocytes were capable of surviving over relatively long time. Positive protein
signals were obtained by Western blot. Conclusions Using lymphocytes as the intermediary, recombined plasmid
pIRES-DsRed2- NT3 is used to establish a lymphocyte line that expresses and secretes NT3. This cell line can be
used in future animal gene cochlear transfection research and may help find an intermediary cell line for gene thera⁃
py for human deafness.
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Neurotrophic factor is very important for development
and functional maintenance of the nervous system. It is
closely involved in neural injury and disease. It not only
plays an important role in the maintenance of normal for⁃
mation and regulation of physiological and biochemical
functions of the inner ear auditory epithelium and neu⁃
rons during embryonic development and after birth, but
also participates in protecting and restoring functions in
a number of acquired disease conditions of the auditory
neuron.
NT3 is a protein family composed by 774 amino acid
residues which are related closely with neurological
structure and function. It has been shown that NT3 has
a significant protective effect for the cochlea, but it has
a short half-life. The specific anatomy of the cochlea
has limited the application of NT3 in the cochlea. It
would be necessary to repeatedly perfuse the cochlea in
order to maintain an effective concentration inside the
cochlea, which would inevitably cause damage to the co⁃
chlea. Transfection of a target gene into the cochlea
therefore represents the only pathway which may pro⁃
vide a long-term supply of the protein factor and main⁃
tain a long-term efficacy of treatment［1-6］.
There is no specific treatment for sensorineural hear⁃
ing loss at present. Recent research has started to focus
on gene therapy and stem cell transplantation. In both
clinical and experimental research, gene transfer is an
exciting new instrument, which is gaining increasing ap⁃
plication in research on preventing and restoring senso⁃
rineural hearing loss in recent years. Transgenic expres⁃
sion is helpful in detecting genes playing a special role
in cochlear cell biology. Such research not only increas⁃
es understanding of the pathophysiology of deafness, but
may also provide gene therapy for inner ear disease［7, 8］.
With the progress of inner ear gene therapy study, it
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has become possible to transfect a target gene into the
cochlea through a gene vector, although the foreign car⁃
rier may potentially harm the host. We chose human
lymphocytes as a carrier of the intermediate host be⁃
cause they are the major cellular components of the en⁃
do-and perilymphatic and cerebrospinal fluid. In case
genetically engineered cells die in the host body, they
will be removed by the immune cells, so there will be no
unknown hazards by the lymphocytes.
The purpose and the significance of this study is that
a stable genetically engineered cells in the form of the
normal lymphocyte that can express and secret NT3 will
be useful in finding an effective way of transferring
genes into the cochlea, which is the foundation for fu⁃
ture clinical application of gene transfer therapy.
Materials and methods
1.1 Materials Human fetal liver tissues were collected
from fresh liver specimen in aborted fetus. The eukary⁃
on vector was purchased from Invitrogen Corporation,
USA. Restriction enzyme EcoRI and BamHI as well as
T4DNA ligase enzyme were purchased from Takara Cor⁃
poration（Japan）. Using the human NT3 sequences in
the genebank（log No, 002527）, the 5，end with a Eco⁃
RI and BamHI restriction sites of PCR primers wsa de⁃
signed, and the primers were synthetized by the Bioasia
Corporation, Shanghai. Recombined eukaryon expres⁃
sion vector pIRES-DsRed2-NT3 was cloned and consti⁃
tuted in our laboratory. Human lymphocytes were ob⁃
tained from the Nanjing Blood Center. Recombined Hu⁃
man IL-2 was purchased from R&D Systems, USA. Li⁃
pofectamine 2000 trasfection kit, fetal calf serum and
RMPI1640 powder were purchased from the Gibco Cor⁃
poration. NT3 antibody was purchased from the Chemi⁃
con Corporation. The ECL LED system was purchased
from the Pierce Corporation.
1.2 Methods
1.2.1 Clone of human NT3 gene The total RNA was
isolated from fresh fetal liver by the Trizol method and
reverse transcribed into cDNA（with random hexmer
primers）. The NT3 gene was amplified by PCR with a
primer at 55℃ over 30 cycles. A fragment of about 774
bp from the PCR products were isolated by electrophore⁃
sis with 1% Agarose gel and purified by gel extraction
kit. Both the purified NT3 PCR production and eukary⁃
otic expression vector pIRES-DsRed2 were digested
with EcoRI and BamHI. Then T4DNA ligase was ap⁃
plied to the digestion mixture for 4 hours and the suc⁃
cess of ligation was verified by gel electrophoresis and
enzyme digestion.
1.2.2 cultivation of human lymphocyte
A Cell extraction Equal volume of concentrated white
blood cell and saline was mixed and the mixture was ap⁃
plied to Ficoll. After centrifuge for 25 min by 2500 rpm,
the mononuclear cell layer（white membrane layer）was
transferred by moving into a new tube.
B Cell washing The cells were washed by saline and
then centrifuged for 5 min at 1500 rpm. After removing
the supernatant, the cells were suspended with RM⁃
PI1640.
C Cell culture The isolated cells were cultured with
10%FCS RMPI1640 at the cell density of 2 × 106 cells／
ml, with Il-2 at 37 oC, 5% CO2.
1.2.3 Gene transfection
Lymphocytes were transfected when cell density
reached 80% . DNA-Lipofectamine 2000 complexes
were prepared as following: 16 ug pIRES-DsRed2 plas⁃
mid DNA was applied to 800 ul of growth medium with⁃
out serum. 48 μl of Lipofectamine 2000 was diluted
with 800 μl growth medium without serum and incubat⁃
ed for 5 minutes at room temperature. Then the diluted
Lipofectamine was applied to plasmid DNA. After incu⁃
bation for 20 minutes at room temperature, the DNA-Li⁃
pofectamine 2000 complexes were applied to cultured
Lymphocytes and incubated at 37℃ in a CO2 incubator
for 48 hours. Transfection was verified by examining
green fluorescence under a fluorescence microscope.
1.2.4 Transfection confirmation The transfection in
human lymphocytes was verified by RT-PCR.
1.2.5 Western Blot analysis Total protein from un⁃
transfected human lymphocytes, transfected human lym⁃
phocytes with NT3 or vector were isolated. 30 ug of pro⁃
tein from each sample was separated by SDS -polyacryl⁃
amide gel electrophoresis and transferred to a nitrocellu⁃
lose membrane. After blocking with skimmed milk, an⁃
ti-NT3 antibodies was added to the membrane and incu⁃
bated. Then horseradish peroxidase（HRP）labeld sec⁃
ond antibody and ECL were applied to the membrane
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for X-ray film exposure.
Results
2.１ Figure 1 shows the NT3-cDNA production ab⁃
stracted from human fresh fetal liver tissue.
2.2 Sequencing the 774bp fragment coding region num⁃
bered“2”and“3”in the NT3-cDNA coincided with
the published sequence number“002”and“527”.
2.3 Figure 3 shows electrophoresis results of constitu⁃
tion of recombined plasmid pIRES-DsRed2-NT3.
2.4 Human lymphocytes grew well and survived at last
3 weeks on on medium containing fetal calf serum and
interleukin -2（IL-2）（Figure. 4）. Figure 5 shows lym⁃
phocytes transfected with NT-3 under a fluorescence
microscope.
2.5 RT-PCR production
Following lymphocyte transfection with NT3 and PCR
reaction, electrophoresis showed a 774 bp fragment, but
not in cells transfected with empty vectors or in
non-transfected human lymphocytes（Figure. 6）.
2.6 Western Blot analysis
There was a clear protein band in the 2nd lane（hu⁃
man lymphocytes transfected with NT3 gene） on the
Figure 1 RT-PCR product from human liver
Figure 2 Construction of the pIRES-DsRed2-NT3 vector
Figure４ Culture of human Lymphocytes
Figure 5 Detection of Lymphocytes transfected with
pIRES-DsRed2-NT3
Figure 3 Analysis of pIRES-DsRed2-NT3 by enzyme di⁃
gestion
1 Standard MMOL of nucleic acid; 2 RT-PCR product from human
liver (784bp)
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X-ray film, with a relative molecular mass of 41 × 103 ,
which was consistent with NT3 protein molecular mass.
In contrast, no positive protein band was seen in lanes
corresponding to cells transfected with empty vector
group and non-transfected human lymphocytes. The re⁃
sults indicate that human lymphocytes transfected with
NT3 have the ability to secret active protein.
Discussion
Neurotrophin-3 is a group of family protein closely
related to neural structure and function, regulating the
development, growth, differentiation and survival of the
neuron. It is not only important for maintaining the sur⁃
vival of auditory epithelial cells and auditory neurons,
but also the most basic nutritional factors for the devel⁃
opment of inner ear［9］.
Auditory signals are formed and transmitted from hair
cells in the auditory receptor organ of Corti to the brain
via the spiral ganglion. Damage or loss of hair cells or
spiral ganglion neurons can cause hearing damage,
which is usually permanent.
NT3 has been confirmed to be an important material
for maintenance of survival of auditory epithelial and au⁃
ditory neurons by in vivo and vitro studies. it has been
shown that giving NT3 protein factor through microinjec⁃
tion or micro-osmotic pump can provide protective and
therapeutic effects for sensorineural hearing loss［2,10-12］.
However, the current administration routes are not
suitable for long-term application, as maintaining a
high level of expression of neurotrophic factors in the co⁃
chlea is critical for treatment success. Cochlea is a spe⁃
cial sensory organ. Derby and Stover injected viral vec⁃
tors carrying a reporter gene into the guinea pig cochlea
and found no change in hearing function and cochlear
morphology. Gene transfer into the cochlea is consid⁃
ered the only way to provide long-term treatments ［4,
13-14］.
The vector systems for gene transfection include viral
and non-viral vector system. While the former carries
relatively high transfection efficiency, its target genes in⁃
troduce and integrate into the host DNA molecule direct⁃
ly. Therefore, its safety remains to be determined. The
advantages of non-viral vector is that it is safe and easy
to conduct, although its biggest problem is the low effi⁃
ciency of transfection.
In this study, we selected liposome LP2000 as the
gene vector, which has low toxicity and high transfec⁃
tion efficiency and expression levels in various cells. It
demonstrates relative high transfection efficiency under
both serum and non-serum conditions［4］.
At the same time we choose lymphocytes as the host
cell for target genes to express and secrete transfected
genes. Such studies usually involve in vitro experiments
because human lymphocytes can be cultured in less
than 1 week. We have established experimental condi⁃
tions that allow us to maintain lymphocytes for 3 weeks
while retaining biological activity. And we continue to
search for favorable experimental conditions to increase
the life cycle of lymphocytes. The current study shows
that human lymphocytes transfected with
pIRES-DsRed2-NT3 could survive under experimental
Figure 6 RT-PCR product from three types of Lympho⁃
cytes
1. Marker; 2. RT-PCR product from Lymphocytes transfected with
NT3-cDNA （784bp）; 3. Lymphocytes transfected with
pIRES-DsRed2-NT3；4. untransfected lymphocytes.
Figure 7 Western blot assay for expression of NT3 protein
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conditions. This represents a useful tool for future gene
transfection studies.
The most important feature and innovation of the cur⁃
rent study is to use the lymphocyte as the intermediate
host of target gene. Transfer via foreign carriers, espe⁃
cially the viral vector, into functional cells directly may
cause potential harm［15］. Direct viral vectors transfer in⁃
to the body may activate the body's immune system
quickly to remove these viral vectors, particularly in⁃
volving the complement system［16］.
Lymphocytes are the main cellular components in the
cerebrospinal fluid and endo- and perilymphatic fluids.
They are the ideal cells for transplantation of genetically
engineered cells in the cochlea. Transplantation of ge⁃
netically engineered lymphocytes into the target organs
in vivo avoids integration of foreign carriers integrate in⁃
to functional cells. If genetically engineered lympho⁃
cytes die, they can be removed by the body's immune
system without the possible harm foreign carriers, espe⁃
cially viral vectors, may produce.
In earlier studies, Gao Xia etc. have reported success⁃
fully recombining and transfecting NT3 gene and pCD
vector into Jurket lymphoma cells, which can easily sur⁃
vive in vitro experiments, to produce genetically engi⁃
neered Jurket lymphoma cells with biological activity.
Studies indicate that intrathecal injection of NT3 delays
aging of cochlear function in inbred mouse［17, 18］. Estab⁃
lishing a genetically engineered lymphocyte line may be
a safe and effective approach to gene therapy for sensori⁃
neural hearing loss.
In this study, our goal is to produce biologically ac⁃
tive NT3-engineered cells using primary cultured hu⁃
man lymphocytes as the transfection target. Our results
show that this is feasible and the resultant cells are ca⁃
pable of expressing NT3 and biologically active. This
work has laid the foundation for future animal studies.
For future research, we plan to build genetically engi⁃
neered lymphocytes in guinea pigs, transplant the cells
into the cochlea, and study effects of transplanted cells
on hearing improvement and corresponding morphologi⁃
cal changes in guinea pigs with hearing loss.as well as
on cochlear homeostasis. We can assume boldly that it
is not impossible to transplante human autologous genet⁃
ically engineered lymphocytes to treat hearing impair⁃
ment in the future.
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